Skip to main content
SpringerLink
Log in

First-line ibrutinib in untreated CLL: QOL improvement at high cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Patel KK, et al. Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia. Blood : 9 Jun 2020. Available from: URL: https://doi.org/10.1182/blood.2020004922

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-line ibrutinib in untreated CLL: QOL improvement at high cost. PharmacoEcon Outcomes News 856, 16 (2020). https://doi.org/10.1007/s40274-020-6916-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6916-0

Search

Navigation